NN9388-7700: Efficacy and safety of co-administered cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (cagrisema s.c. 2.4 mg/2.4 mg) once-weekly compared to semaglutide, cagrilinitide and placebo in people with chronic kidney disease an

NCT06131372

NN9388-7700: Efficacy and safety of co-administered cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (cagrisema s.c. 2.4 mg/2.4 mg) once-weekly compared to semaglutide, cagrilinitide and placebo in people with chronic kidney disease and type 2 diabetes.

Principal Investigator

Sponsor

Novo Nordisk

Study Purpose: The purpose of this study is to see whether CagriSema can lower kidney damage. This will be compared to the effects of semaglutide, cagrilintide and placebo.

Study Duration: Approximately 35 weeks

Study Commitment: 10 outpatient visits
3 phone calls

Age: 18+ years old

Sex: Male & Female

Conditions/Eligibility: You have chronic kidney disease.
You have type 2 diabetes.
Your Body Mass Index is at least 27 kg/m2.

Study Procedures: Informed consent
Medical history and medication review
Questionnaires and medication diary
Electrocardiogram (ECG)
Eye exams
Urine and blood collections

Compensation: Up to $1,300.00